The U.S. Food and Drug Administration on August 19, 2026 authorized Aletta, a Utrecht-based Vitestro's autonomous robotic phlebotomy device, as the first stand-alone robot allowed to draw blood from a patient's arm without hands-on operator intervention. The marketing authorization, granted through the FDA's De Novo pathway, creates an entirely new regulatory category for robotic phlebotomy and clears Aletta for use in adults in outpatient settings.
Aletta Handles Every Step Of The Draw
Aletta autonomously performs each stage of a blood draw, from vein identification to bandage placement. Near-infrared imaging combined with Doppler ultrasound locates a suitable vein and distinguishes it from an artery. If no appropriate vein is found, the device refuses to attempt the procedure. Once a vein is identified, Aletta applies a tourniquet, prepares the skin, inserts and disposes of the needle, changes collection tubes and applies a bandage. A supervising phlebotomist confirms tube order and adequacy.
The device is designed with multiple layers of patient safety. Disinfectant is continuously applied during the ultrasound scan, and the needle automatically detaches if a patient moves during the procedure. Sensors can pause the draw and alert the supervisor if any unsafe condition is detected.
Addressing A Phlebotomist Shortage
A single trained phlebotomist can oversee up to three Aletta devices simultaneously — a workflow the agency described as a potential answer to the growing shortage of trained blood draw staff across U.S. hospitals and labs. "Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists," said Michelle Tarver, M.D., Ph.D., director of the FDA's Center for Devices and Radiological Health.
Clinical Data And Global Rollout
The FDA authorization is based on clinical data showing Aletta achieves successful draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick, across a broad range of patient types, including those with self-reported difficult vein access and varying skin tones. Adverse events were uncommon and mild. A peer-reviewed study published in Clinical Chemistry earlier this year reported 94.5% first-stick success.
Aletta has been CE-marked in the European Union since 2025 and is already deployed at hospitals including OLVG Lab, Amsterdam UMC and Denmark's Odense University Hospital, which pre-ordered three units in Vitestro's first international deployment. Northwestern Medicine has also announced a multi-year collaboration to bring the device to the U.S. market.
The FDA is establishing special controls that define labeling, performance and clinical-testing requirements for future robotic phlebotomy devices — a signal that Vitestro's approval may open the door to a wider category of autonomous medical robotics. The clearance lands the same week Aletta's healthcare peers, including ZEISS Clinic 360, Vessl Prosthetics' Kinn socket and Implicity's ILR analyzer, have also received FDA nods.
Reporting based on coverage from the U.S. Food and Drug Administration, GlobeNewswire and Citeline.